---
title: "Claseprubart (DNTH103) in Generalized myasthenia gravis: Conclusions"
description: "Formulary evidence on Claseprubart (DNTH103) in Generalized myasthenia gravis: Conclusions. 1 evidence topic quoted from 17 sources."
canonical: "https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/executive-summary/conclusions"
published: "2026-11-15T22:20:57-05:00"
modified: "2026-11-15T22:20:57-05:00"
---

# Claseprubart (DNTH103) in Generalized myasthenia gravis: Conclusions

<a id="heading-1.1.4"></a>

## 1.1.4 Conclusions

<a id="topic-1.1.4-1"></a>

### Summary

An estimated 82,715 US adults were living with myasthenia gravis in 2021, and up to 80% of patients with ocular onset go on to develop generalized symptoms, usually within two years. After weighting, patients with generalized myasthenia gravis had more than 4-fold higher healthcare costs than non-gMG controls ($5420 compared with $1298 per patient per month), with higher costs among those with exacerbation or crisis and among those with any glucocorticoid use. 10% to 20% of patients continue to have long-standing moderate or severe weakness after treatment with at least two different immunosuppressive drugs at high doses, and upward of thirty percent of patients do not benefit from complement inhibition. Soliris increases the risk of serious meningococcal infections and, like Zilbrysq, is available only through a REMS program. ICER estimated incremental cost-effectiveness ratios of $5,210,000 per QALY/evLYG for eculizumab and $2,076,000 per QALY/evLYG for efgartigimod at a placeholder price.

Claseprubart is an investigational classical pathway inhibitor targeting active C1s, administered by subcutaneous injection. In the 65-participant phase 2 MaGic trial, both doses improved MG-ADL and QMG compared with placebo at week 13; participants who continued claseprubart showed sustained improvement at open-label extension week 52 (65 total weeks on treatment); no participant receiving claseprubart had a treatment-related serious adverse event or discontinued for an adverse event during the randomized period; and among participants antinuclear antibody negative at baseline, 1 of 17 (5.9%) receiving 300 mg and 8 of 22 (36.4%) receiving 600 mg tested positive at a titer of at least 1:320, with no symptoms indicative of autoimmune activation. The phase 3 EMERGE trial began in June 2026, with top-line results expected in the second half of 2028. No phase 3 results, peer-reviewed full article, price, or budget impact model for claseprubart was identified, so comparative efficacy and cost against complement C5 inhibitors and FcRn blockers cannot yet be assessed.

Source: [Ye et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10907989/); [Dresser et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8196750/); [Dianthus Therapeutics (2026g)](https://www.sec.gov/Archives/edgar/data/1690585/000169058526000039/dnth-ex99_1.htm); [Dianthus Therapeutics presentation (2026e)](https://investor.dianthustx.com/static-files/9868f92c-aaba-4dcb-87a6-6881536645d1); [Barnett-Tapia et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13498700/); [Jackson et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/41099443/); [Zhdanava et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38745448/); [Silvestri et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13008238/); [Gilhus et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11236053/); [Kaminski et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11178544/); [Soliris prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/125166s454lbl.pdf); [Zilbrysq prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/216834s015lbl.pdf); [Tice et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10373007/); [Dianthus Therapeutics (2025b)](https://www.sec.gov/Archives/edgar/data/1690585/000119312525197751/d933929dex991.htm); [Vu et al. (2026b)](https://investor.dianthustx.com/static-files/2aa268f8-9efe-4897-b3e9-5c576d4f94bc); [Peric et al. (2026e)](https://investor.dianthustx.com/static-files/2908a226-f34c-4b2e-9de3-69bd0bf53e0e); [Dianthus Therapeutics Form 10-Q (2026c)](https://www.sec.gov/Archives/edgar/data/1690585/000169058526000040/dnth-20260930.htm)

## Related pages
- [Claseprubart (DNTH103): Generalized myasthenia gravis](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis) · [Markdown](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis.md)
- [Claseprubart (DNTH103) in Generalized myasthenia gravis: Terms and abbreviations](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/terms-and-abbreviations.md)
- [Claseprubart (DNTH103): Generalized myasthenia gravis](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/executive-summary) · [Markdown](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/executive-summary.md)
- [Claseprubart (DNTH103) in Generalized myasthenia gravis: Product information and disease description](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/product-information-and-disease-description.md)
- [Claseprubart (DNTH103) in Generalized myasthenia gravis: Clinical evidence](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/clinical-evidence.md)
- [Claseprubart (DNTH103) in Generalized myasthenia gravis: Economic information and modeling report](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/economics) · [Markdown](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/economics.md)
- [Claseprubart (DNTH103) in Generalized myasthenia gravis: References](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/references) · [Markdown](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/references.md)
